148 related articles for article (PubMed ID: 12538677)
1. Broadening of epitope recognition during immune rejection of ErbB-2-positive tumor prevents growth of ErbB-2-negative tumor.
Pilon SA; Kelly C; Wei WZ
J Immunol; 2003 Feb; 170(3):1202-8. PubMed ID: 12538677
[TBL] [Abstract][Full Text] [Related]
2. Vaccination with cytoplasmic ErbB-2 DNA protects mice from mammary tumor growth without anti-ErbB-2 antibody.
Pilon SA; Piechocki MP; Wei WZ
J Immunol; 2001 Sep; 167(6):3201-6. PubMed ID: 11544306
[TBL] [Abstract][Full Text] [Related]
3. Complementary antitumor immunity induced by plasmid DNA encoding secreted and cytoplasmic human ErbB-2.
Piechocki MP; Pilon SA; Wei WZ
J Immunol; 2001 Sep; 167(6):3367-74. PubMed ID: 11544327
[TBL] [Abstract][Full Text] [Related]
4. Critical components of a DNA fusion vaccine able to induce protective cytotoxic T cells against a single epitope of a tumor antigen.
Rice J; Buchan S; Stevenson FK
J Immunol; 2002 Oct; 169(7):3908-13. PubMed ID: 12244189
[TBL] [Abstract][Full Text] [Related]
5. Identification and characterization of the immunodominant rat HER-2/neu MHC class I epitope presented by spontaneous mammary tumors from HER-2/neu-transgenic mice.
Ercolini AM; Machiels JP; Chen YC; Slansky JE; Giedlen M; Reilly RT; Jaffee EM
J Immunol; 2003 Apr; 170(8):4273-80. PubMed ID: 12682262
[TBL] [Abstract][Full Text] [Related]
6. HSP110-HER2/neu chaperone complex vaccine induces protective immunity against spontaneous mammary tumors in HER-2/neu transgenic mice.
Manjili MH; Wang XY; Chen X; Martin T; Repasky EA; Henderson R; Subjeck JR
J Immunol; 2003 Oct; 171(8):4054-61. PubMed ID: 14530326
[TBL] [Abstract][Full Text] [Related]
7. Potent CD4+ T-cell epitope P30 enhances HER2/neu-engineered dendritic cell-induced immunity against Tg1-1 breast cancer in transgenic FVBneuN mice by enhanced CD4+ T-cell-stimulated CTL responses.
Xie Y; Chen Y; Ahmed KA; Li W; Ahmed S; Sami A; Chibbar R; Tang X; Tao M; Xu J; Xiang J
Cancer Gene Ther; 2013 Oct; 20(10):590-8. PubMed ID: 24052129
[TBL] [Abstract][Full Text] [Related]
8. The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors.
Reilly RT; Machiels JP; Emens LA; Ercolini AM; Okoye FI; Lei RY; Weintraub D; Jaffee EM
Cancer Res; 2001 Feb; 61(3):880-3. PubMed ID: 11221874
[TBL] [Abstract][Full Text] [Related]
9. Intralesional injection of adenovirus encoding CC chemokine ligand 16 inhibits mammary tumor growth and prevents metastatic-induced death after surgical removal of the treated primary tumor.
Guiducci C; Di Carlo E; Parenza M; Hitt M; Giovarelli M; Musiani P; Colombo MP
J Immunol; 2004 Apr; 172(7):4026-36. PubMed ID: 15034014
[TBL] [Abstract][Full Text] [Related]
10. HER-2 DNA and protein vaccines containing potent Th cell epitopes induce distinct protective and therapeutic antitumor responses in HER-2 transgenic mice.
Renard V; Sonderbye L; Ebbehøj K; Rasmussen PB; Gregorius K; Gottschalk T; Mouritsen S; Gautam A; Leach DR
J Immunol; 2003 Aug; 171(3):1588-95. PubMed ID: 12874253
[TBL] [Abstract][Full Text] [Related]
11. A single heteroclitic epitope determines cancer immunity after xenogeneic DNA immunization against a tumor differentiation antigen.
Gold JS; Ferrone CR; Guevara-Patiño JA; Hawkins WG; Dyall R; Engelhorn ME; Wolchok JD; Lewis JJ; Houghton AN
J Immunol; 2003 May; 170(10):5188-94. PubMed ID: 12734366
[TBL] [Abstract][Full Text] [Related]
12. Priming MHC-I-restricted cytotoxic T lymphocyte responses to exogenous hepatitis B surface antigen is CD4+ T cell dependent.
Wild J; Grusby MJ; Schirmbeck R; Reimann J
J Immunol; 1999 Aug; 163(4):1880-7. PubMed ID: 10438922
[TBL] [Abstract][Full Text] [Related]
13. DNA fusion vaccines induce targeted epitope-specific CTLs against minor histocompatibility antigens from a normal or tolerized repertoire.
Rice J; Buchan S; Dewchand H; Simpson E; Stevenson FK
J Immunol; 2004 Oct; 173(7):4492-9. PubMed ID: 15383580
[TBL] [Abstract][Full Text] [Related]
14. A single vaccination with polyomavirus VP1/VP2Her2 virus-like particles prevents outgrowth of HER-2/neu-expressing tumors.
Tegerstedt K; Lindencrona JA; Curcio C; Andreasson K; Tullus C; Forni G; Dalianis T; Kiessling R; Ramqvist T
Cancer Res; 2005 Jul; 65(13):5953-7. PubMed ID: 15994974
[TBL] [Abstract][Full Text] [Related]
15. Induction of specific immune responses by polycation-based vaccines.
Lührs P; Schmidt W; Kutil R; Buschle M; Wagner SN; Stingl G; Schneeberger A
J Immunol; 2002 Nov; 169(9):5217-26. PubMed ID: 12391240
[TBL] [Abstract][Full Text] [Related]
16. Definition of key variables for the induction of optimal NY-ESO-1-specific T cells in HLA transgene mice.
Johannsen A; Genolet R; Legler DF; Luther SA; Luescher IF
J Immunol; 2010 Sep; 185(6):3445-55. PubMed ID: 20733200
[TBL] [Abstract][Full Text] [Related]
17. CD4+ T cell-mediated HER-2/neu-specific tumor rejection in the absence of B cells.
Lindencrona JA; Preiss S; Kammertoens T; Schüler T; Piechocki M; Wei WZ; Seliger B; Blankenstein T; Kiessling R
Int J Cancer; 2004 Mar; 109(2):259-64. PubMed ID: 14750178
[TBL] [Abstract][Full Text] [Related]
18. Relevance of the tumor antigen in the validation of three vaccination strategies for melanoma.
Bellone M; Cantarella D; Castiglioni P; Crosti MC; Ronchetti A; Moro M; Garancini MP; Casorati G; Dellabona P
J Immunol; 2000 Sep; 165(5):2651-6. PubMed ID: 10946294
[TBL] [Abstract][Full Text] [Related]
19. DNA vaccination against rat her-2/Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice.
Rovero S; Amici A; Di Carlo E; Bei R; Nanni P; Quaglino E; Porcedda P; Boggio K; Smorlesi A; Lollini PL; Landuzzi L; Colombo MP; Giovarelli M; Musiani P; Forni G
J Immunol; 2000 Nov; 165(9):5133-42. PubMed ID: 11046045
[TBL] [Abstract][Full Text] [Related]
20. Identification of a ras oncogene peptide that contains both CD4(+) and CD8(+) T cell epitopes in a nested configuration and elicits both T cell subset responses by peptide or DNA immunization.
Bristol JA; Orsini C; Lindinger P; Thalhamer J; Abrams SI
Cell Immunol; 2000 Nov; 205(2):73-83. PubMed ID: 11104579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]